Study reveals provider perceptions of
commercially available biosimilars and anticipated launches, which
have the potential to increase equitable access to critical
treatments
DUBLIN,
Ohio, Feb. 22, 2023 /PRNewswire/ -- Today,
Cardinal Health (NYSE: CAH) released its 2023 Biosimilars
Report: Tracking market expansion and sustainability amidst a
shifting industry, a publication that highlights provider
perceptions, utilization and the latest market trends of
biosimilars. The report assesses new and changing perspectives
regarding some of the most disruptive biosimilars launched in the
areas of immunology and ophthalmology, noting a growing familiarity
of the medications among rheumatologists with 76% reporting being
very familiar with the products, a 43% jump year-over-year. The
research also reports high familiarity among gastroenterologists
(81%) compared to ophthalmologists (33%) and dermatologists
(31%).
"Biosimilars bring competition and lower costs to
patient-critical treatments," said Bruce
Feinberg, chief medical officer and vice president of
Cardinal Health. "In order to deliver on the promise of these drugs
from a health equity standpoint, we must continue to analyze
prescriber awareness and familiarity. Through our research,
Cardinal Health seeks to understand prescribers' perceptions and
what other factors are moving the industry forward—from business
and financial decisions to provider adoption."
Cardinal Health surveyed more than 350 providers across
rheumatology, gastroenterology, dermatology and ophthalmology. The
responses offer new analysis, insights into market growth, drivers
of adoption, and obstacles that remain in the market. The new
report also includes an updated analysis of biosimilar market
adoption and key milestones achieved throughout 2022, and
highlights how policy and updated formulary announcements may
impact patient access of these critical therapeutics.
In addition to general provider perceptions, this
report provides in-depth analysis of how up to 10
Humira™ (adalimumab) biosimilars launching in 2023 may affect
the market with provider input on the most important product
attributes for each therapeutic area (e.g. latex and citrate-free
solutions).
The 2023 Biosimilars Report also contains:
- A lookback at five key milestones achieved in 2022, including
how the Enhancing Oncology Model might continue the growth and
adoption of biosimilars in the oncology market
- A detailed examination of how the Inflation Reduction Act could
affect the biosimilars market
- Commentary from industry stakeholders on the single most
critical action needed to ensure a sustainable U.S. biosimilars
market
- An updated pipeline of biosimilars expected to come to market
in the next three years
The report can be accessed at
www.cardinalhealth.com/biosimilarsreport
About Cardinal Health
Cardinal Health is a distributor
of pharmaceuticals, a global manufacturer and distributor of
medical and laboratory products, and a provider of performance and
data solutions for healthcare facilities. With more than 50 years
in business, operations in more than 30 countries and approximately
46,500 employees globally, Cardinal Health is essential to care.
Information about Cardinal Health is available
at cardinalhealth.com
Media Contact:
Tara Parsell
Tara.parsell@cardinalhealth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-cardinal-health-report-examines-shifts-in-biosimilars-industry-301752744.html
SOURCE Cardinal Health